TY - JOUR
T1 - Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma
T2 - A Single-Institution Review
AU - Pinnix, Chelsea C.
AU - Shah, Jatin J.
AU - Chuang, Hubert
AU - Costelloe, Colleen M.
AU - Medeiros, L. Jeffrey
AU - Wogan, Christine F.
AU - Reed, Valerie
AU - Smith, Grace L.
AU - Milgrom, Sarah
AU - Patel, Krina
AU - Huo, Jinhai
AU - Turturro, Francesco
AU - Romaguera, Jorge
AU - Fayad, Luis
AU - Oki, Yasuhiro
AU - Fanale, Michelle A.
AU - Westin, Jason
AU - Nastoupil, Loretta
AU - Hagemeister, Fredrick B.
AU - Rodriguez, Alma
AU - Qazilbash, Muzaffar
AU - Shah, Nina
AU - Bashir, Qaiser
AU - Ahmed, Sairah
AU - Nieto, Yago
AU - Hosing, Chitra
AU - Rohren, Eric
AU - Dabaja, Bouthaina
N1 - Funding Information:
This work was supported in part by the National Cancer Institute, National Institutes of Health [Cancer Center Support (Core) Grant CA016672] to The University of Texas MD Anderson Cancer Center.
Publisher Copyright:
© 2016 Elsevier Inc. All rights reserved.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Background Plasmablastic lymphoma (PBL) is an aggressive variant of diffuse large B-cell lymphoma. We sought to assess the treatment outcomes after combined-modality therapy for early-stage PBL. Materials and Methods We retrospectively reviewed the outcomes of 10 consecutive patients diagnosed with stage I-II PBL from February 2001 to December 2013 at a single institution. The baseline clinical characteristics, treatment modalities, overall outcomes, and treatment-related toxicity were assessed. Results The median age at diagnosis was 50.5 years. All patients had extranodal disease; 2 were positive for human immunodeficiency virus. Seven patients received hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone)-based chemotherapy, 2 received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and 1 received dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). Radiotherapy (RT) was administered after a complete response to chemotherapy in 7 patients and a partial response in 1 patient. At a median follow-up period of 42 months, the estimated 2-year progression-free and overall survival rates were 90% and 100%, respectively. Conclusion PBL can be successfully treated with aggressive chemotherapy followed by RT. The treatment was well tolerated and can result in long-term survival for patients with limited-stage disease.
AB - Background Plasmablastic lymphoma (PBL) is an aggressive variant of diffuse large B-cell lymphoma. We sought to assess the treatment outcomes after combined-modality therapy for early-stage PBL. Materials and Methods We retrospectively reviewed the outcomes of 10 consecutive patients diagnosed with stage I-II PBL from February 2001 to December 2013 at a single institution. The baseline clinical characteristics, treatment modalities, overall outcomes, and treatment-related toxicity were assessed. Results The median age at diagnosis was 50.5 years. All patients had extranodal disease; 2 were positive for human immunodeficiency virus. Seven patients received hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone)-based chemotherapy, 2 received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), and 1 received dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin). Radiotherapy (RT) was administered after a complete response to chemotherapy in 7 patients and a partial response in 1 patient. At a median follow-up period of 42 months, the estimated 2-year progression-free and overall survival rates were 90% and 100%, respectively. Conclusion PBL can be successfully treated with aggressive chemotherapy followed by RT. The treatment was well tolerated and can result in long-term survival for patients with limited-stage disease.
KW - Combined modality therapy
KW - Early stage
KW - Non-Hodgkin lymphoma
KW - Radiotherapy
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84958862129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958862129&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2015.12.008
DO - 10.1016/j.clml.2015.12.008
M3 - Article
C2 - 26795083
AN - SCOPUS:84958862129
SN - 2152-2650
VL - 16
SP - 122
EP - 128
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 3
ER -